Maria L. Cataldo
Naples, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Impact of trop-2 expression on the efficacy of trop-2-targeted antibody-drug conjugates in metastatic breast cancer: a systematic review and meta-analysis.
Journal: Journal of the National Cancer Institute
Published: February 17, 2026
Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 20, 2025
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysis.
Journal: EClinicalMedicine
Published: July 15, 2025
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer.
Journal: Frontiers in oncology
Published: November 25, 2022
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer.
Journal: Cell reports
Published: November 17, 2021
NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer.
Journal: Scientific reports
Published: September 15, 2021
Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 02, 2021
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 02, 2020
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: December 13, 2019
Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 02, 2019
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.
Journal: British journal of cancer
Published: April 25, 2018
Showing 1-11 of 11
Last Updated: 09/26/2026